Impact of genomics on the surgical management of melanoma

Downsizing of locally advanced stage III (bulky) BRAF V600E/K melanoma with combination targeted therapy to achieve R0 resection

(2017) J. Haanen et al.   EUROPEAN JOURNAL OF CANCER

Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992-2013

(2017) Shoshana M. Landow et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

(2017) Reinhard Dummer et al.   LANCET ONCOLOGY

Whole-genome landscapes of major melanoma subtypes

(2017) Nicholas K. Hayward et al.   NATURE

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

(2017) Jeffrey Weber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma

(2017) Mark B. Faries et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

(2017) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity

(2017) Claire Vanpouille-Box et al.   Nature Communications

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression

(2017) Georgina V. Long et al.   JAMA Oncology

Advances in immunotherapy for melanoma

(2016) Jason M. Redman et al.   BMC Medicine

Abstract CT004: KEYNOTE-006: PD-L1 expression and efficacy in patients (Pts) treated with pembrolizumab (pembro) vs ipilimumab (IPI) for advanced melanoma

(2016) Matteo Carlino et al.   CANCER RESEARCH

Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial:

(2016) F. Stephen Hodi et al.   CANCER RESEARCH

Management of toxicities of immune checkpoint inhibitors

(2016) Lavinia Spain et al.   CANCER TREATMENT REVIEWS

The rapidly evolving therapies for advanced melanoma—Towards immunotherapy, molecular targeted therapy, and beyond

(2016) Ziqiang Zhu et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Rationale for anti-GITR cancer immunotherapy

(2016) Deborah A. Knee et al.   EUROPEAN JOURNAL OF CANCER

BRAFV600EandNRASQ61L/Q61Rmutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting

(2016) Hojabr Kakavand et al.   HISTOPATHOLOGY

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

(2016) Antoni Ribas et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Overall Survival and Durable Responses in Patients WithBRAFV600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib

(2016) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

(2016) Weijie Ma et al.   Journal of Hematology & Oncology

Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort

(2016) Shelley Ji Eun Hwang et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials

(2016) Georgina V Long et al.   LANCET ONCOLOGY

Gene Expression Profiling in Cutaneous Melanoma: Caveats for Clinicians

(2016) Sindhuja Sominidi-Damodaran et al.   MAYO CLINIC PROCEEDINGS

A diagnostic algorithm for atypical spitzoid tumors: guidelines for immunohistochemical and molecular assessment

(2016) Jeong Hee Cho-Vega   MODERN PATHOLOGY

microRNA-10b is a prognostic biomarker for melanoma

(2016) Gerald Saldanha et al.   MODERN PATHOLOGY

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

(2016) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Advances in melanoma: revolutionary progress delivering improved patient management and outcomes

(2016) Richard A. Scolyer et al.   PATHOLOGY

The molecular profile of metastatic melanoma in Australia

(2016) Megan Lyle et al.   PATHOLOGY

Melanoma progression

(2016) David E. Elder   PATHOLOGY

Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy

(2016) Benjamin Y. Kong et al.   Pigment Cell & Melanoma Research

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease

(2016) J. Liu et al.   Cancer Discovery

NRAS and EPHB6 mutation rates differ in metastatic melanomas of patients in the North Island versus South Island of New Zealand

(2016) Angela M. Jones et al.   Oncotarget

Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature

(2016) Joshua E. Reuss et al.   Journal for ImmunoTherapy of Cancer

Genomic Classification of Cutaneous Melanoma

(2015) Rehan Akbani et al.   CELL

Development of a Prognostic Genetic Signature to Predict the Metastatic Risk Associated with Cutaneous Melanoma

(2015) P. Gerami et al.   CLINICAL CANCER RESEARCH

Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis

(2015) Omar Abdel-Rahman et al.   Immunotherapy

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

(2015) Dirk Schadendorf et al.   JOURNAL OF CLINICAL ONCOLOGY

More People Die from Thin Melanomas (≤1 mm) than from Thick Melanomas (>4 mm) in Queensland, Australia

(2015) David C. Whiteman et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

(2015) Georgina V Long et al.   LANCET

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Genetic Evolution of Melanoma from Precursor Lesions

(2015) A. Hunter Shain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma

(2015) M. R. Girotti et al.   Cancer Discovery

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma

(2015) Elin S. Gray et al.   Oncotarget

Glucocorticoid-Induced Tumour Necrosis Factor Receptor-Related Protein: A Key Marker of Functional Regulatory T Cells

(2015) Simona Ronchetti et al.   Journal of Immunology Research

Molecular Pathways: CDK4 Inhibitors for Cancer Therapy

(2014) M. A. Dickson   CLINICAL CANCER RESEARCH

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape

(2014) Deepak Mittal et al.   CURRENT OPINION IN IMMUNOLOGY

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

Guidance for laboratories performing molecular pathology for cancer patients

(2014) Ian A Cree et al.   JOURNAL OF CLINICAL PATHOLOGY

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study

(2014) Pippa G Corrie et al.   LANCET ONCOLOGY

CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy

(2014) Christine E Engeland et al.   MOLECULAR THERAPY

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

(2014) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma

(2014) Alexander M. Menzies et al.   PLoS One

Risk Assessment for Atypical Spitzoid Melanocytic Neoplasms Using FISH to Identify Chromosomal Copy Number Aberrations

(2013) Pedram Gerami et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Intrapatient Homogeneity of BRAFV600E Expression in Melanoma

(2013) Alexander M. Menzies et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Chimeric Antigen Receptor Therapy for Cancer

(2013) David M. Barrett et al.   Annual Review of Medicine

Vaccines against advanced melanoma

(2013) Tatiana Blanchard et al.   CLINICS IN DERMATOLOGY

Spontaneous regression of metastatic melanoma – Clinical evidence of the abscopal effect

(2013) R.J. Bramhall et al.   EJSO

Resistance to BRAF-targeted therapy in melanoma

(2013) Ryan J. Sullivan et al.   EUROPEAN JOURNAL OF CANCER

Endocrine Side Effects Induced by Immune Checkpoint Inhibitors

(2013) Salvatore Maria Corsello et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A Genome-Wide High-Resolution Array-CGH Analysis of Cutaneous Melanoma and Comparison of Array-CGH to FISH in Diagnostic Evaluation

(2013) Lu Wang et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Circulating Melanoma Cells in the Diagnosis and Monitoring of Melanoma: An Appraisal of Clinical Potential

(2013) Brigid S. Mumford et al.   Molecular Diagnosis & Therapy

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Hazard-Rate Analysis and Patterns of Recurrence in Early Stage Melanoma: Moving towards a Rationally Designed Surveillance Strategy

(2013) April K. S. Salama et al.   PLoS One

Tumor Homogeneity between Primary and Metastatic Sites for BRAF Status in Metastatic Melanoma Determined by Immunohistochemical and Molecular Testing

(2013) Lucile Boursault et al.   PLoS One

Surgery for Distant Melanoma Metastasis

(2012) Anna M. Leung et al.   CANCER JOURNAL

A Landscape of Driver Mutations in Melanoma

(2012) Eran Hodis et al.   CELL

Vaccination with Irradiated Tumor Cells Pulsed with an Adjuvant That Stimulates NKT Cells Is an Effective Treatment for Glioma

(2012) M. K. Hunn et al.   CLINICAL CANCER RESEARCH

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

(2012) T. Shimizu et al.   CLINICAL CANCER RESEARCH

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

(2012) A. M. Menzies et al.   CLINICAL CANCER RESEARCH

The role of cytology specimens in molecular testing of solid tumors: Techniques, limitations, and opportunities

(2012) Dara L. Aisner et al.   DIAGNOSTIC CYTOPATHOLOGY

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Advances in the Treatment of Metastatic Melanoma: Adoptive T-Cell Therapy

(2012) Chantale Bernatchez et al.   SEMINARS IN ONCOLOGY

Enhanced Detection of Spitzoid Melanomas Using Fluorescence In Situ Hybridization With 9p21 as an Adjunctive Probe

(2011) Bryan Gammon et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

(2011) S. A. Rosenberg et al.   CLINICAL CANCER RESEARCH

Sentinel Lymph Nodes in Cutaneous Melanoma

(2011) Victor G. Prieto   CLINICS IN LABORATORY MEDICINE

KIT as a Therapeutic Target in Metastatic Melanoma

(2011) Richard D. Carvajal   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Melanoma MicroRNA Signature Predicts Post-Recurrence Survival

(2010) M. F. Segura et al.   CLINICAL CANCER RESEARCH

MicroRNA Expression Profiles Associated with Mutational Status and Survival in Malignant Melanoma

(2010) Stefano Caramuta et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells

(2010) Ruth Halaban et al.   Pigment Cell & Melanoma Research

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Final Version of 2009 AJCC Melanoma Staging and Classification

(2009) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY

Allogeneic Melanoma Vaccine Expressing αGal Epitopes Induces Antitumor Immunity to Autologous Antigens in Mice Without Signs of Toxicity

(2009) Gabriela R. Rossi et al.   JOURNAL OF IMMUNOTHERAPY

Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse

(2009) Friederike Egberts et al.   MELANOMA RESEARCH

Spontaneous regression of metastases from melanoma: review of the literature

(2009) Louise Vennegaard Kalialis et al.   MELANOMA RESEARCH

Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group

(2008) Alessandro Testori et al.   JOURNAL OF CLINICAL ONCOLOGY

MicroRNA Expression in Melanocytic Nevi: The Usefulness of Formalin-Fixed, Paraffin-Embedded Material for miRNA Microarray Profiling

(2008) Martin Glud et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Antigens for cancer immunotherapy

(2008) Michelle A. Neller et al.   SEMINARS IN IMMUNOLOGY